You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1908 Results
Regimen
Regimen
Cancer Type:
Gastrointestinal, 
Anus
Intent: Palliative
Funding:
ODB - General Benefit
    capecitabine
Apr 2023
Regimen
Cancer Type:
Central Nervous System
Intent: Palliative
Jul 2024
Regimen
Cancer Type:
Gynecologic, 
Ovary
Intent: Palliative
Funding:
New Drug Funding Program
    Bevacizumab (Biosimilar) with Paclitaxel and Carboplatin - Front-line Treatment (Previously Untreated) Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Jul 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Nov 2023
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Hypersensitivity Reactions to Taxanes
Dec 2024
Regimen
Intent: Palliative
Funding:
New Drug Funding Program
    Nab-Paclitaxel - Metastatic Breast Cancer
Sep 2025
Regimen
Cancer Type:
Genitourinary, 
Renal cell / Kidney
Intent: Palliative
Funding:
Exceptional Access Program
    SUNItinib - Metastatic renal cell carcinoma, with specific criteria
Oct 2020
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Intent: Palliative, Curative
Funding:
New Drug Funding Program
    Trastuzumab (Biosimilar) - Advanced or Recurrent Endometrial Cancer
Oct 2024
Regimen
Regimen
Cancer Type:
Sarcoma, 
Ewing's, 
Soft Tissue
Intent: Neoadjuvant, Adjuvant, Palliative
Jun 2019
Regimen
Cancer Type:
Gastrointestinal, 
Pancreas
Intent: Palliative
Funding:
New Drug Funding Program
    Gemcitabine and Nab-Paclitaxel - Advanced Pancreatic Cancer
Jan 2024

Pages